Catalyst
Slingshot members are tracking this event:
Allergan's (AGN) XEN Gel Stent Approved by FDA to Reduce Intraocular Pressure (IOP) in Treatment-Resistant Glaucoma Patients
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AGN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 22, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Xen Gel Stent, Intraocular Pressure, Glaucoma, Treatment-resistant
